Skip to main content
OpenTrials
Completed

NCT Number: NCT05854810

Frozen Embryo Transfer in PCOS Patients

Polycystic ovarian syndrome (PCOS) is condition characterized by being complex, familial and polygenetic metabolic condition with heterogeneous involvement of several genes in the hypothalamic-pituitary-gonadal axis. PCOS is the most incident endocrine-metabolic syndrome that is characterized by hyperandrogenemia, menstrual irregularities, and/or small cysts in one or both ovaries and could be considered as the main cause of female infertility.

Assisted reproductive technologies (ART) were defined by the American Center for Disease Control as any fertility-related treatments where eggs or embryos are manipulated. In vitro fertilization involves the transfer of fresh embryos, however, the freeze-all strategy that entails cryopreservation of all embryos to be transferred subsequently in un-stimulated cycle to guard against the negative effects of controlled ovarian stimulation on the endometrium and to minimize the risk of ovarian hyper-stimulation syndrome. Intracytroplasmatic sperm injection (ICSI) is a common procedure used to improve reproductive results, even among couples without male factor infertility.

However, there are several points of controversy in the fields of ART traditionally, multiple embryo transfer strategy was used to increase the chance for getting a baby, however, multiple pregnancy is a common complication for this strategy with subsequent adverse fetal, maternal and neonatal outcomes. Also, the developmental stage of embryos at time of transfer; cleavage versus blastocyst was a matter of debit, but giving the chance for in-vitro maturation to the stage of blastocyst increased the possibility of getting good quality embryo to be transferred. However, the exaggeration of prolongation of the in-vitro duration appeared as a trend, but recent studies found no advantages for transfer of D7 or D6 blastocyst over D5 blastocyst transfer (BT).

Completed

Looking for future studies?

Notify Me

Key information

Age range

20 year–35 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Zagazig University

Zagazig, Ash Sharqia Governorate, 44519, Egypt

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Infertile women fulfilling at least two of the Rotterdam criteria for diagnosis of PCOS;
  • aged 20-35 years;
  • had body mass index (BMI) of less than 35 kg/m2;
  • mild hirsutism on Ferriman-Gallwey (FG) visual scoring system;
  • their hormonal profile of serum AMH >4.5, FSH <5.85 LH>5.39;
  • had no previous attempts of ICSI were included in the study.

Exclusion criteria

  • Patients who were out of the predetermined age range and BMI;
  • had uterine abnormalities;
  • hydrosaplnix;
  • recurrent miscarriage;
  • medical diseases interfering with or being complicated by occurrence of pregnancy;
  • cases requiring ICSI with TESE samples;
  • had obesity-inducing endocrinopathy
  • severe symptomatizing hypovitaminosis or maintained on hormonal contraception within the last 6 months before inclusion in the study, were excluded from the study.

Treatment and study plan

fertilized embryo Insertion

Procedure

insertion of single fertilized embryo through IVF

Primary outcomes

  1. the live birth rate (LBR) after SBT and DBT

    Time frame: 9 months

Sponsors and collaborators

Lead sponsor

Zagazig University

Other Gov

Registry information

Official study title

Single Versus Double Frozen Embryo Transfer in PCOS Patients

Important dates

Study start
2019
Primary completion
2022
Study completion
2022
First posted
May 11, 2023
Registry last updated
May 11, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.